大B细胞淋巴瘤结外累及部位特异性分析揭示嵌合抗原受体T细胞疗法的不同疗效
这项多中心研究纳入516例接受CD19靶向CAR-T治疗的复发/难治性大B细胞淋巴瘤患者,按结外累及情况分为仅淋巴结组177例、仅结外组66例和淋巴结+结外组273例。淋巴结+结外组较仅淋巴结组总生存更短(HR 1.41,95%CI 1.05-1.88,p=0.02),无进展生存无统计学显著差异(HR 1.27,95%CI 0.98-1.64,p=0.07);仅结外组与仅淋巴结组疗效无差异。结外部位数目增多及特定器官(肝、肾上腺、胰腺)累及与更短的无进展生存相关。
要点
- 淋巴结+结外同时累及者较仅淋巴结累及者总生存更短(HR 1.41,p=0.02)
- 结外部位数目增多及肝、肾上腺、胰腺累及与更短无进展生存相关
- 仅结外累及与仅淋巴结累及者之间未发现疗效差异
核心结论
- CAR-T治疗时同时存在淋巴结和结外累及的患者结局更差,但该队列具有高危基线特征;结外部位数目增多和特定疾病部位与较低的CAR-T疗效相关。
研究设计与样本
- 多中心研究纳入516例接受CD19靶向CAR-T治疗的复发/难治性大B细胞淋巴瘤患者。
- 按CAR-T治疗时结外累及情况分组:仅淋巴结组177例(34%)、仅结外组66例(13%)、淋巴结+结外组273例(53%)。
主要发现
- 淋巴结+结外组较仅淋巴结组总生存更短(HR 1.41,95%CI 1.05-1.88,p=0.02)。
- 淋巴结+结外组较仅淋巴结组无进展生存无统计学显著差异(HR 1.27,95%CI 0.98-1.64,p=0.07)。
- 仅结外组与仅淋巴结组之间未发现疗效差异。
- 结外部位数目增多及特定器官(肝、肾上腺、胰腺)累及与更短的无进展生存相关。
- 复发时结外累及增加,各部位清除率呈现异质性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over 60% of relapsed/refractory large B-cell lymphoma (R/R LBCL) patients treated with chimeric antigen receptor (CAR) T-cells experience progressive disease. The impact of site-specific extranodal involvement on CAR-T outcomes has not been fully elucidated. This multicenter study included 516 R/R LBCL patients infused with CD19-targeted CAR T-cells; 177 (34%) had only-nodal (N), 66 (13%) only-extranodal (E) and 273 (53%) nodal and extranodal (NE) disease at time of CAR T-cells. The NE cohort included more patients with a poor performance status and high tumor burden. In the multivariable analysis, the NE group had a shorter progression-free survival (PFS) (HR 1.27 [95%CI 0.98-1.64], p = 0.07) and overall survival (HR 1.41 [95%CI 1.05-1.88], p = 0.02) compared to N. Conversely, we did not identify efficacy differences between N and E patients. A higher number of extranodal sites and specific organ involvement (liver, adrenal glands, pancreas), were associated with shorter PFS. Finally, extranodal involvement increased at time of relapse, displaying heterogeneous individual site clearance rates. In conclusion, patients with concomitant nodal and extranodal involvement at time of CAR-T had worse outcomes, but this cohort harbored high-risk baseline characteristics. An increasing number of extranodal sites and certain disease locations were associated with lower CAR-T efficacy.
引用
- Iacoboni G, Rejeski K, Navarro V, et al. Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy. Leukemia. 2025. PMID: 40169762. doi:10.1038/s41375-025-02582-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。